These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 3497150)
1. Comparative effects of quinolones on human mononuclear leucocyte functions. Roche Y; Gougerot-Pocidalo MA; Fay M; Etienne D; Forest N; Pocidalo JJ J Antimicrob Chemother; 1987 Jun; 19(6):781-90. PubMed ID: 3497150 [TBL] [Abstract][Full Text] [Related]
2. Enhancement of interleukin 2 production by quinolone-treated human mononuclear leukocytes. Roche Y; Fay M; Gougerot-Pocidalo MA Int J Immunopharmacol; 1988; 10(2):161-7. PubMed ID: 3131260 [TBL] [Abstract][Full Text] [Related]
3. Effects of quinolones on interleukin 1 production in vitro by human monocytes. Roche Y; Fay M; Gougerot-Pocidalo MA Immunopharmacology; 1987 Apr; 13(2):99-109. PubMed ID: 3496323 [TBL] [Abstract][Full Text] [Related]
4. [Modulation by quinolones of the in vitro proliferative response of splenic cells of the mouse and IL 1 production]. Guenounou M; Ronco E; Kodari E; Vacheron F; Momrikof V Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):785-9. PubMed ID: 3309816 [TBL] [Abstract][Full Text] [Related]
5. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans]. Renaudin H; Quentin C; de Barbeyrac B; Bebear C Pathol Biol (Paris); 1988 May; 36(5):496-9. PubMed ID: 3136430 [TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activity of ciprofloxacin, ofloxacin and pefloxacin against resistant clinical isolates. Periti P; Mazzei T; Nicoletti P Chemioterapia; 1987 Apr; 6(2):75-8. PubMed ID: 3474081 [TBL] [Abstract][Full Text] [Related]
7. Effects of quinolones on granulocyte function in vitro. Boogaerts MA; Malbrain S; Scheers W; Verwilghen RL Infection; 1986; 14 Suppl 4():S258-62. PubMed ID: 3469158 [TBL] [Abstract][Full Text] [Related]
8. [In vitro antibacterial activity of 2 new quinolones: A 56619 (difloxacin) and A 56620. Comparison with pefloxacin, ofloxacin and ciprofloxacin]. Soussy CJ; Deforges L; Le Van Thoi J; Duval J Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):759-67. PubMed ID: 3309811 [TBL] [Abstract][Full Text] [Related]
9. The influence of the 4-quinolones ciprofloxacin, pefloxacin and ofloxacin on the elimination of theophylline. Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL Pharm Weekbl Sci; 1987 Dec; 9 Suppl():S72-5. PubMed ID: 3481439 [TBL] [Abstract][Full Text] [Related]
10. [Comparative bactericidal kinetics of ciprofloxacin, ofloxacin and pefloxacin alone and in combination against strains of group D Streptococcus]. Zuccarelli M; Simeon de Buochberg M; Maillols M; Armynot du Chatelet AM; Attisso MA Pathol Biol (Paris); 1988 May; 36(5):403-9. PubMed ID: 3136422 [TBL] [Abstract][Full Text] [Related]
11. In vitro activity of four fluoroquinolones against eighty-six isolates of mycobacteria. Texier-Maugein J; Mormède M; Fourche J; Bébéar C Eur J Clin Microbiol; 1987 Oct; 6(5):584-6. PubMed ID: 3125050 [TBL] [Abstract][Full Text] [Related]
12. The comparative pharmacokinetics of five quinolones. Wise R; Lister D; McNulty CA; Griggs D; Andrews JM J Antimicrob Chemother; 1986 Nov; 18 Suppl D():71-81. PubMed ID: 3468102 [TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile. Edlund C; Nord CE Scand J Infect Dis; 1986; 18(2):149-51. PubMed ID: 2939556 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of five new quinolones against cultivable mycobacteria. Pattyn SR; Van Caekenberghe DL; Verhoeven JR Eur J Clin Microbiol; 1987 Oct; 6(5):572-3. PubMed ID: 3125049 [No Abstract] [Full Text] [Related]
15. [Post-antibiotic effect of ciprofloxacin alone and in combination on Streptococcus faecalis]. Zuccarelli M; Simeon de Buochberg M; Maillols H; Dusart G; Attisso MA Pathol Biol (Paris); 1988 May; 36(5):410-3. PubMed ID: 3136423 [TBL] [Abstract][Full Text] [Related]
16. [Sensitivity of 7 mycobacterial species to new quinolones]. Gevaudan MJ; Mallet MN; Gulian C; Terriou P; Lagier P; de Micco P Pathol Biol (Paris); 1988 May; 36(5):477-81. PubMed ID: 3136429 [TBL] [Abstract][Full Text] [Related]
17. In-vitro activity of newer quinolones against aerobic bacteria. Auckenthaler R; Michéa-Hamzehpour M; Pechère JC J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214 [TBL] [Abstract][Full Text] [Related]
18. A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microflora. Edlund C; Nord CE Infection; 1988; 16(1):8-12. PubMed ID: 3283041 [TBL] [Abstract][Full Text] [Related]
19. Comparative in-vitro activity of five fluoroquinolones against mycobacteria. Davies S; Sparham PD; Spencer RC J Antimicrob Chemother; 1987 May; 19(5):605-9. PubMed ID: 3112094 [TBL] [Abstract][Full Text] [Related]
20. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline. Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL Drugs; 1987; 34 Suppl 1():159-69. PubMed ID: 3481317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]